Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER.
CLEOCIN PHOSPHATE vs CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, a lincosamide antibiotic. It reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
1200-2700 mg/day IV divided every 6-12 hours; typical adult dose: 600-900 mg IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age.
Terminal elimination half-life is 2-4 hours in adults with normal hepatic and renal function. In patients with severe hepatic impairment, half-life may increase to 8-12 hours. Renal impairment generally does not significantly alter half-life. In neonates, half-life ranges from 8-20 hours depending on gestational age.
Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route.
Approximately 10% of the administered dose is excreted unchanged in urine via glomerular filtration; about 90% is metabolized hepatically to inactive metabolites, which are excreted in bile and feces. Biliary excretion accounts for approximately 80% of total elimination, with enterohepatic recirculation.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic